JBIO earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -6.80. Updated 2026-07-23.
Jade Biosciences (JBIO) Research Hub
Jade Biosciences (JBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 17.89 USD (-6.14%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.80, market cap 0.64B. This hub links to the full technical, earnings and options research available for JBIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 17.89 USD (-6.14%) |
| 52-week range | 15.27 USD – 24.94 USD |
| Trend regime | Range |
| 14-day RSI | 28 (Oversold) |
| Trailing P/E | -6.80 |
| Market cap | 0.64B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for JBIO
Covered Call on JBIO: how it works, illustrative setup around the real 17.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on JBIO: how it works, illustrative setup around the real 17.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on JBIO: how it works, illustrative setup around the real 17.89 USD price, max profit/loss, breakeven and when to use it. Educational.
JBIO technical analysis: range, last 17.89 USD, RSI 28, 52w range 15.27 USD–24.94 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is JBIO in?
Jade Biosciences (JBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is JBIO in an uptrend or downtrend?
As of 2026-09-11, JBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is JBIO's trailing P/E ratio?
JBIO's trailing P/E is -6.80, with a market cap of 0.64B. See the earnings research page for full valuation detail.
When does JBIO next report earnings?
JBIO is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.66 USD.